- Home
- JEQ vs GALT Comparison
JEQ vs GALT Comparison
Compare JEQ & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JEQ
- GALT
- Stock Information
- Founded
- JEQ 1990
- GALT 2000
- Country
- JEQ United States
- GALT United States
- Employees
- JEQ N/A
- GALT N/A
- Industry
- JEQ Air Freight/Delivery Services
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- JEQ Consumer Discretionary
- GALT Health Care
- Exchange
- JEQ Nasdaq
- GALT Nasdaq
- Market Cap
- JEQ 88.1M
- GALT 86.0M
- IPO Year
- JEQ N/A
- GALT N/A
- Fundamental
- Price
- JEQ $6.93
- GALT $1.38
- Analyst Decision
- JEQ
- GALT Hold
- Analyst Count
- JEQ 0
- GALT 1
- Target Price
- JEQ N/A
- GALT N/A
- AVG Volume (30 Days)
- JEQ 32.0K
- GALT 173.6K
- Earning Date
- JEQ 01-01-0001
- GALT 05-19-2025
- Dividend Yield
- JEQ 7.05%
- GALT N/A
- EPS Growth
- JEQ N/A
- GALT N/A
- EPS
- JEQ N/A
- GALT N/A
- Revenue
- JEQ N/A
- GALT N/A
- Revenue This Year
- JEQ N/A
- GALT N/A
- Revenue Next Year
- JEQ N/A
- GALT N/A
- P/E Ratio
- JEQ N/A
- GALT N/A
- Revenue Growth
- JEQ N/A
- GALT N/A
- 52 Week Low
- JEQ $4.99
- GALT $0.73
- 52 Week High
- JEQ $6.39
- GALT $3.41
- Technical
- Relative Strength Index (RSI)
- JEQ 67.34
- GALT 49.81
- Support Level
- JEQ $6.81
- GALT $1.26
- Resistance Level
- JEQ $6.90
- GALT $1.63
- Average True Range (ATR)
- JEQ 0.08
- GALT 0.13
- MACD
- JEQ 0.03
- GALT 0.02
- Stochastic Oscillator
- JEQ 98.20
- GALT 37.50
About JEQ abrdn Japan Equity Fund Inc.
Aberdeen Japan Equity Fund Inc is a United States-based closed-end diversified management investment company. Its investment objective is to outperform over the long term, on a total return basis (including appreciation and dividends), the Tokyo Stock Price Index ("TOPIX"). The fund seeks to achieve its investment objective by investing a majority of its assets, in equity securities of companies listed on the Tokyo Stock Exchange or listed on the over-the-counter market in Japan or listed on other stock exchanges in Japan. The portfolio of investments is spread across Consumer Discretionary, Industrials, Information Technology, Financials, and other sectors.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.